Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.37 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31454441 | 1.00 | IDO1 (0.41) | IDO1CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL4703980 | 0.81 | CYP3A4 (0.41) | IDO1CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL31454434 | 0.79 | IDO1 (0.41) | IDO1CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL4280341 | 0.79 | IDO1 (0.40) | IDO1CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL2997812 | 0.79 | CYP2A6 (0.44) | IDO1CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL1197989 | 0.79 | IDO1 (0.41) | IDO1CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL1995097 | 0.79 | IDO1 (0.40) | IDO1CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL1539432 | 0.77 | IDO1 (0.46) | IDO1CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL3366516 | 0.76 | IDO1 (0.38) | IDO1CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL283639 | 0.75 | IDO1 (0.62) | IDO1CYP3A4CYP2C9MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854789-A1 | MACROCYCLIC COMPOUNDS USEFUL AS CHITINASE INHIBITORS | CYGNET BIOSCIENCES B.V. (CW) | 2021-07-28 | — | — | EP | disclosed |
| CN-101356164-A | Novel compounds | ASTRAZENECA AB (SE) | 2009-01-28 | — | — | CN | disclosed |
| US-20080255150-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1948630-A2 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| CN-101035774-A | Modulators of CRTH-2 receptor activity for the treatment of prostaglandin D2 mediated diseases | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | CN | disclosed |
| EP-1799658-A2 | MODULATORS OF CRTH2 REZEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007052023-A2 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006037982-A2 | MODULATORS OF CRTH2 RECEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | PTGDR2, PTGDR, PTGER2 | IDO1 3349/4885CYP3A4 2766/4885CYP2C9 2328/4885 |
| US-20080255150-A1 | Novel Compounds | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 | IDO1 1120/4885CYP3A4 23/4885CYP2C9 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.